Estimated Number of COVID-19 Infections, Hospitalizations, and Deaths Prevented Among Vaccinated Persons in the US, December 2020 to September 2021.


Journal

JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235

Informations de publication

Date de publication:
01 07 2022
Historique:
entrez: 6 7 2022
pubmed: 7 7 2022
medline: 9 7 2022
Statut: epublish

Résumé

The number of SARS-CoV-2 infections and COVID-19-associated hospitalizations and deaths prevented among vaccinated persons, independent of the effect of reduced transmission, is a key measure of vaccine impact. To estimate the number of SARS-CoV-2 infections and COVID-19-associated hospitalizations and deaths prevented among vaccinated adults in the US. In this modeling study, a multiplier model was used to extrapolate the number of SARS-CoV-2 infections and COVID-19-associated deaths from data on the number of COVID-19-associated hospitalizations stratified by state, month, and age group (18-49, 50-64, and ≥65 years) in the US from December 1, 2020, to September 30, 2021. These estimates were combined with data on vaccine coverage and effectiveness to estimate the risks of infections, hospitalizations, and deaths. Risks were applied to the US population 18 years or older to estimate the expected burden in that population without vaccination. The estimated burden in the US population 18 years or older given observed levels of vaccination was subtracted from the expected burden in the US population 18 years or older without vaccination (ie, counterfactual) to estimate the impact of vaccination among vaccinated persons. Completion of the COVID-19 vaccination course, defined as 2 doses of messenger RNA (BNT162b2 or mRNA-1273) vaccines or 1 dose of JNJ-78436735 vaccine. Monthly numbers and percentages of SARS-CoV-2 infections and COVID-19-associated hospitalizations and deaths prevented were estimated among those who have been vaccinated in the US. COVID-19 vaccination was estimated to prevent approximately 27 million (95% uncertainty interval [UI], 22 million to 34 million) infections, 1.6 million (95% UI, 1.4 million to 1.8 million) hospitalizations, and 235 000 (95% UI, 175 000-305 000) deaths in the US from December 1, 2020, to September 30, 2021, among vaccinated adults 18 years or older. From September 1 to September 30, 2021, vaccination was estimated to prevent 52% (95% UI, 45%-62%) of expected infections, 56% (95% UI, 52%-62%) of expected hospitalizations, and 58% (95% UI, 53%-63%) of expected deaths in adults 18 years or older. These findings indicate that the US COVID-19 vaccination program prevented a substantial burden of morbidity and mortality through direct protection of vaccinated individuals.

Identifiants

pubmed: 35793085
pii: 2793913
doi: 10.1001/jamanetworkopen.2022.20385
pmc: PMC9260489
doi:

Substances chimiques

Ad26COVS1 JT2NS6183B
COVID-19 Vaccines 0
Influenza Vaccines 0
BNT162 Vaccine N38TVC63NU

Types de publication

Journal Article Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2220385

Subventions

Organisme : CDC HHS
Pays : United States

Commentaires et corrections

Type : CommentIn

Références

Clin Infect Dis. 2022 Apr 28;74(8):1382-1389
pubmed: 34282839
Med (N Y). 2021 Aug 13;2(8):979-992.e8
pubmed: 34223401
MMWR Morb Mortal Wkly Rep. 2021 Aug 27;70(34):1156-1162
pubmed: 34437524
Vaccine. 2018 Nov 19;36(48):7331-7337
pubmed: 30327213
Clin Infect Dis. 2021 Jun 15;72(12):e1010-e1017
pubmed: 33237993
JAMA Netw Open. 2021 Nov 1;4(11):e2132540
pubmed: 34726743
Emerg Infect Dis. 2009 Dec;15(12):2004-7
pubmed: 19961687
N Engl J Med. 2021 Dec 9;385(24):2300-2301
pubmed: 34670040
MMWR Morb Mortal Wkly Rep. 2021 Aug 27;70(34):1163-1166
pubmed: 34437519
Lancet. 2021 Oct 16;398(10309):1407-1416
pubmed: 34619098
Ann Intern Med. 2021 Oct;174(10):1404-1408
pubmed: 34280332
BMJ. 2021 Aug 20;374:n1943
pubmed: 34417165
BMC Med. 2021 Oct 18;19(1):275
pubmed: 34663326
Health Aff (Millwood). 2021 Sep;40(9):1465-1472
pubmed: 34406840
Emerg Infect Dis. 1999 Sep-Oct;5(5):607-25
pubmed: 10511517
MMWR Morb Mortal Wkly Rep. 2021 Jan 01;69(5152):1657-1660
pubmed: 33382671
Lancet Reg Health Am. 2022 Feb;6:100134
pubmed: 34849505
MMWR Morb Mortal Wkly Rep. 2021 Sep 17;70(37):1284-1290
pubmed: 34529637
N Engl J Med. 2021 Dec 16;385(25):e90
pubmed: 34551224
JMIR Public Health Surveill. 2022 Jun 2;8(6):e34296
pubmed: 35452402
MMWR Morb Mortal Wkly Rep. 2021 May 21;70(20):753-758
pubmed: 34014909
N Engl J Med. 2021 Jul 22;385(4):320-329
pubmed: 34192428
J Infect Dis. 2021 Sep 08;:
pubmed: 34498052

Auteurs

Molly K Steele (MK)

COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, Georgia.
Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.

Alexia Couture (A)

COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, Georgia.
Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.

Carrie Reed (C)

COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, Georgia.
Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.

Danielle Iuliano (D)

COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, Georgia.
Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.
US Public Health Service, Rockville, Maryland.

Michael Whitaker (M)

COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, Georgia.
Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.

Hannah Fast (H)

COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, Georgia.
Immunization Services Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.

Aron J Hall (AJ)

COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, Georgia.
Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.

Adam MacNeil (A)

COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, Georgia.
Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.

Betsy Cadwell (B)

COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, Georgia.
Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.

Kristin J Marks (KJ)

COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, Georgia.
US Public Health Service, Rockville, Maryland.
Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia.
Division of Nutrition, Physical Activity, and Obesity, National Center for Chronic Disease Prevention and Health Promotion, Atlanta, Georgia.

Benjamin J Silk (BJ)

COVID-19 Emergency Response, Centers for Disease Control and Prevention, Atlanta, Georgia.
Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.
US Public Health Service, Rockville, Maryland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH